GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Sino Biopharmaceutical Ltd (OTCPK:SBMFF) » Definitions » Tax Expense

Sino Biopharmaceutical (Sino Biopharmaceutical) Tax Expense : $111 Mil (TTM As of Jun. 2023)


View and export this data going back to 2010. Start your Free Trial

What is Sino Biopharmaceutical Tax Expense?

Sino Biopharmaceutical's tax expense for the months ended in Jun. 2023 was $73 Mil. Its tax expense for the trailing twelve months (TTM) ended in Jun. 2023 was $111 Mil.


Sino Biopharmaceutical Tax Expense Historical Data

The historical data trend for Sino Biopharmaceutical's Tax Expense can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Sino Biopharmaceutical Tax Expense Chart

Sino Biopharmaceutical Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Tax Expense
Get a 7-Day Free Trial Premium Member Only Premium Member Only 128.71 102.82 307.39 111.31 111.66

Sino Biopharmaceutical Semi-Annual Data
Jun14 Dec14 Jun15 Dec15 Jun16 Dec16 Jun17 Dec17 Jun18 Dec18 Jun19 Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23
Tax Expense Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 97.49 85.34 29.35 73.27 38.17

Sino Biopharmaceutical Tax Expense Calculation

Tax paid by the company. It is computed in by multiplying the income before tax number, as reported to shareholders, by the appropriate tax rate. In reality, the computation is typically considerably more complex due to things such as expenses considered not deductible by taxing authorities ("add backs"), the range of tax rates applicable to various levels of income, different tax rates in different jurisdictions, multiple layers of tax on income, and other issues.

Tax Expense for the trailing twelve months (TTM) ended in Jun. 2023 adds up the semi-annually data reported by the company within the most recent 12 months, which was $111 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Sino Biopharmaceutical  (OTCPK:SBMFF) Tax Expense Explanation

In the long run, income before tax and taxable income will likely be more similar than they are in any given period. If the one is less in earlier years, then it will be greater in later years. Deferred taxes will reverse themselves in the long run and in total will zero out, unless there is something like a change in tax rates in the intervening period. A deferred tax payable results from a tax break in the early years and will reverse itself in later years; a deferred tax receivable results from more taxes being paid in early years than the tax expense reported to shareholders and will again reverse itself in later years. The deferred tax amount is computed by estimating the amount and the timing of the reversal and multiplying that by the appropriate tax rates.


Sino Biopharmaceutical Tax Expense Related Terms

Thank you for viewing the detailed overview of Sino Biopharmaceutical's Tax Expense provided by GuruFocus.com. Please click on the following links to see related term pages.


Sino Biopharmaceutical (Sino Biopharmaceutical) Business Description

Traded in Other Exchanges
Address
1 Harbour Road, Unit 09, 41st Floor, Office Tower, Room 4109, Convention Plaza, Wanchai, Hong Kong, HKG
Sino Biopharmaceutical Co, or SBP, is one of the largest drugmakers in China, with CNY 27 billion revenue in 2021. Its four most important therapeutic areas are oncology, hepatitis, cardio-cerebral, and respiratory medicines. SBP's current portfolio is mostly generics, and some key drugs are facing severe price reductions. However, it also has a rich pipeline of early-to-market generics and biosimilars, especially in oncology and respiratory treatments.

Sino Biopharmaceutical (Sino Biopharmaceutical) Headlines

From GuruFocus

GuruFocus Value Idea Contest Sees 2 Winners!

By Holly LaFon Holly LaFon 07-12-2019

Matthews China Fund 3rd Quarter Commentary

By Holly LaFon Holly LaFon 10-19-2017

Matthews China Fund Comments on Sino Biopharmaceutical

By Vera Yuan Vera Yuan 10-20-2014

Matthews China Fund Comments on Sino Biopharmaceutical

By Sydnee Gatewood Sydnee Gatewood 01-28-2020

Matthews China Fund Comments on Sino Biopharmaceutical

By Sydnee Gatewood Sydnee Gatewood 10-25-2019

Value Idea Contest: Sino Biopharmaceutical

By Matthew Sipos Matthew Sipos 01-10-2019